Therapeutical capacities of intranasal glucocorticoids in patients with allergic rhinitis


Cite item

Full Text

References

  1. European Allergy White Paper. Allergic diseases as a public health problem. The UCB Institute of Allergy. Belgium; 1997. 14-47.
  2. Bousquet J., van Cauwenberge P., Khaltaev N. et al. Management of allergic rhinitis and its impact on asthma. 2001.
  3. International consensus report on diagnosis and management of rhinitis. Allergy 1994; 49 (19, suppl.): 1-34.
  4. Barnes P. J. Efficacy of inhaled corticosteroids in asthma. Allergy Clin. Immunol. 1998; 102 (4, pt 1): 531-538.
  5. Barnes P. J., Pedersen S., Basse W. W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157 (3, pt 2): 1-53.
  6. Bertorelli G., Bocchino V., Olivieri D. Heat shock protein interactions with the glucocorticoid receptor. Pulm. Pharm. Ther. 1998; 11 (1): 7-12.
  7. Adcock I. M. Molecular mechanisms of glucocorticoid actions. Ibid. 2000; 13 (3): 115-126.
  8. Rahman I., MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53 (7): 601-612.
  9. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Ibid. 2000; 55 (7): 603-613.
  10. Сергеев П. В., Духанин А. С., Шимановский Н. Л. Плазматическая мембрана клетки-мишени и стероидные гормоны: начало спора или его завершение? Бюл. экспер. биол. 1995; 10: 342-345.
  11. Lamry W. R. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 1999; 104 (4, pt 2): 150-158.
  12. Kelly N. W. Comparison of inhaled steroids. Ann. Pharmacother. 1998; 32 (2): 220-232.
  13. Kelly H. W. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled steroids. J. Allergy Clin. Immunol. 1998; 102 (4, pt 2): 36-51.
  14. Crocker I. C., Church M. K., Newton S., Townley R. G. Glucocorticoids inhibit proliferation and interleukin 4 and interleukin 5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann. Allergy Asthma Immunol. 1998; 80 (6): 509-516.
  15. Umland S. P., Nahrebne D. K., Razflc S. et al. The inhibitory effects of topically active glucocorticoids on IL 4, IL 5, and interferon-gamma production by cultured primary CD4+ T cells. J. Allergy Clin. Immunol. 1997; 100 (4): 511-519.
  16. Allen D. Systemic effects of intranasal steroids: an endocrinologist's perspective. Ibid. 2000; 106 (4): 179-190.
  17. Corren J. Allergic rhinitis: treating the adult. Ibid. 105 (6, pt 2): 610-615.
  18. LaForce С. Use of nasal steroids in managing allergic rhinitis. Ibid. 1999; 103 (3, pt 2): 338-394
  19. Naclerio R. Rhinocort-a clinical monograph. Oxford, UK; 32-35.
  20. Newman S. P., Moren F., Clarke S. W. Deposition pattern from a nasal pump spray. Rhinology 1987; 25 (1): 77-82.
  21. Mygind N. Glucocorticoids and rhinitis. Allergy 1993; 48 (2): 476-490.
  22. van Cauwenberg P., Bachert C., Passalacqua G. et al. Consensus statement on the treatment of allergic rhinitis. Ibid. 2000; 55 (2): 116-129.
  23. Durham S. R. Effect of intranasal corticosteroid treatment on asthma in children and adults. Ibid. 1999; 54 (57): 124-131.
  24. Meltzer E. O. An overview of current pharmacology in perennial rhinitis. J. Allergy Clin. Immunol. 1995; 95 (5, pt 2): 97- 1110.
  25. Passalacqua G., Albano M., Canonica G. W. et al. Position paper. Inhaled and nasal steroids: safety aspects. Allergy 2000; 55 (1); 16-32.
  26. Wihl J. A., Andersson К. Е., Johanssson S. A. Systemic effects of two nasally administered glucocorticosteroids. Ibid. 1997; 52 (6): 620-626.
  27. Wilson A. M., McFarlane L. C., Lipworth B. J. Effect of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J. Allergy Clin. Immunol. 1998; 101 (4, pt 1): 470-474.
  28. Brannan M. D., Seiberling M., Cuttler D. L. et al. Lack of systemic activity with intranasal mometasone furoate. Ibid. 1996; 97 (1): 198.
  29. Brannan M. D., Herron J. M., Reidenberg P., Affine M. B. Lack of HPA axis supression following 36 days of intranasal mometasone furoate. Ann. Allergy Asthma Immunol. 1997; 78 (1): 154.
  30. Shenkel E. J., Skoner D. P., Bronsky E. A. et al. Absence of growth retardation in children with perennial allergic rhinitis after one year treatment with momethasone furoate agueous nasal spray. Pediatrics [electronic pages] 2000; 105: 22.
  31. Skoner D. P., Rachelefsky G. S., Meltzer E. O. et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Ibid. 23.
  32. Wolthers O. D., Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, deport and intranasal glucocorticoids. Acta Paediatr. 1993; 82 (8): 635-640.
  33. Knutsson U., Stierna P., Markus С. et al. Effect of intranasal glucocorticoids on endogenous glucocorticoid pareferal and central function. J. Endocrinol. 1995; 144 (2): 301-310.
  34. Wilson A. M., Sims E. J., McFarlane L. C., Lipworth B. J. Effect of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J. Allergy Clin. Immunol. 1998; 102 (4, pt 1): 598-604.
  35. Brattsand R. The ideal steroid. Pulm. Pharm. Ther. 1999; 12 (20): 119-122.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies